The Italian Cohort (ITACO) and the Analytical Antiretroviral Treatment Interruption Italian Cohort (ITACO-ATI) study guided by molecular HIV-1 reservoir profiling

perinatally HIV infection

1. ITACO cohort: Proportion of patients with absence or HIV intact proviruses, isolated from at least 20 million peripheral blood mononuclear cells (PBMCs), located in heterochromatin positions, which include (i) all non-genic positions, (ii) positions in ZNF genes on chromosome 19, which display extensive binding to heterochromatin proteins and associated with repressive histone modifications (PredictHIV negative) 2. ITACO-ATI cohort: Proportion of patients “PredictHIV negative” who underwent A

1. ITACO cohort: • Proportion of patients with virus inducibility (TILDA assay) in the whole cohort and with distinct latency reversal agents (LRAs) in vitro • Proportion of patients with GALT with absence of intact HIV provirus • Adverse events and serious adverse events 2. ITACO-ATI cohort: • Time from ART discontinuation (start of ATI) to HIV RNA rebound to ≥ 1,000 copies/mL. • Time from ART discontinuation to meeting criteria for ART re-initiation. • Proteomic and In Vitro Gene Expre

No related papers found yet.

Papers published before 2007-09-01 may not appear yet. Historical indexing is in progress.

Italy